Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial.

Trial Profile

Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2012 Accrual to date is 90% as reported by United Kingdom Clinical Research Network.
    • 20 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 08 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top